These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34479728)

  • 1. Severe asthma and biologics: Data are good, listening to patients is better.
    Bukstein DA; Guerra DG
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):285-286. PubMed ID: 34479728
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric Severe Asthma in the Era of Biologic Treatments.
    Teague WG
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):118-120. PubMed ID: 32953228
    [No Abstract]   [Full Text] [Related]  

  • 3. Urgent need for pragmatic trial platforms in severe asthma.
    Pilette C; Brightling C; Lacombe D; Brusselle G
    Lancet Respir Med; 2018 Aug; 6(8):581-583. PubMed ID: 30070256
    [No Abstract]   [Full Text] [Related]  

  • 4. Going Beyond "Bio-markers," Think "Life-markers".
    Tan L; Chupp G; Castro M; Kraft M
    Chest; 2020 Mar; 157(3):503-505. PubMed ID: 32145809
    [No Abstract]   [Full Text] [Related]  

  • 5. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
    Dávila I; Quirce S; Olaguibel JM
    J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
    [No Abstract]   [Full Text] [Related]  

  • 6. Asthma biologics: Underuse, overuse, and best use?
    Rank MA; Oppenheimer JJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):358-359. PubMed ID: 30578858
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

  • 9. ICER Can Do Better for Patients.
    Mendez K
    J Manag Care Spec Pharm; 2019 May; 25(5):514-516. PubMed ID: 31039068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asthma-related death trends and biologics use for severe asthma in the super-aged society of Japan.
    Kan-O K
    Respirology; 2024 Jun; 29(6):455-457. PubMed ID: 38651273
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined approach to define the clinical impact and decision making in asthmatics.
    Clini E; Fabbri LM
    Minerva Med; 2021 Oct; 112(5):539-541. PubMed ID: 34814632
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 16. Biologics in severe asthma: Which one, When and Where?
    Rupani H; Murphy A; Bluer K; Renwick C; McQuitty P; Jackson DJ; Heaney LG; Chaudhuri R; Menzies-Gow A; Calvert J; Siddiqui S
    Clin Exp Allergy; 2021 Sep; 51(9):1225-1228. PubMed ID: 34289191
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Development and Biologics in Asthma. A New Era.
    Doyle R
    Ann Am Thorac Soc; 2016 Mar; 13 Suppl 1():S83-4. PubMed ID: 27027958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of sputum periostin to anti-T2 biologics treatment in severe asthma.
    Nair P; Radford K; Nunomura S; Mukherjee M; Izuhara K
    Allergy; 2024 Oct; 79(10):2842-2844. PubMed ID: 38651839
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologics, Clinical Context, and the Asthmas.
    Casale TB; Israel E
    J Allergy Clin Immunol Pract; 2019; 7(5):1437-1439. PubMed ID: 31076059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.